As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.
Zacks.com on MSN6d
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback